PressJuly 7, 2025 Algernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
PressJuly 7, 2025 Atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
PressJuly 7, 2025 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
PressJuly 7, 2025 SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
PressJuly 7, 2025 Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM
PressJuly 7, 2025 Filament Health Announces First Quarter 2025 Financial Results and Operational Highlights
PressJuly 7, 2025 Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
PressJune 5, 2025 Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
PressApril 30, 2025 Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
PressApril 30, 2025 SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
PressApril 23, 2025 Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
PressApril 23, 2025 Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
PressApril 23, 2025 Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
PressApril 23, 2025 Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
